title: Advances in LDL-apheresis for the treatment of severe hypercholesterolemia.
abstract: LDL-apheresis is an extracorporeal plasma-perfusion method that selectively removes apolipoprotein B-containing lipoproteins from the blood. It is indicated for patients with homozygous and drug-resistant heterozygous familial hypercholesterolemia. Clinical and angiographic regression of coronary artery disease has been demonstrated in patients treated with cholesterol-lowering programs that include LDL-apheresis.
authors.affiliation: The Rogosin Institute, New York Hospital-Cornell Medical Center, New York, New York 10021, USA.
authors.forename: B R
authors.initials: BR
authors.lastname: Gordon
authors.forename: S D
authors.initials: SD
authors.lastname: Saal
mesh_terms: D001055:Apolipoproteins B / Q000097:blood*; D001781:Blood Component Removal / Q000379:methods; D008078:Cholesterol, LDL / Q000378:metabolism; D002986:Clinical Trials as Topic; D003327:Coronary Disease / Q000628:therapy; D006801:Humans; D006938:Hyperlipoproteinemia Type II / Q000628:therapy*; D008077:Lipoproteins, LDL / Q000097:blood*
chemical_list: D001055:Apolipoproteins B; D008078:Cholesterol, LDL; D008077:Lipoproteins, LDL